Chondroitin sulfate is a glycosaminoglycan that constitutes an important structural component of the extracellular cartilage matrix and is responsible for its resistance to compression.
As we age, our cartilage starts to wear down and can lead to the onset of degenerative joint diseases like osteoarthritis. It has been proven that chondroitin sulfate can help slow this process.
Efficacy
Chondroitin sulfate-API is considered a Symptomatic Slow Acting Drug for Osteoarthritis.
For people suffering from joint disorders, such as osteoarthritis, it offers an effective and welcome treatment for joint pain.
Chondroitin sulfate-API is currently recommended by national and international therapeutic guidelines, with clinical trials showing its effectiveness in reducing joint pain and increasing mobility.
Chondroitin sulfate-API from Bioiberica is the chemical reference in the European Pharmacopoeia. It is available from bovine or porcine origin and capable for use for pharmaceuticals and injectable products.
Bioiberica also offers nutraceutical quality chondroitin sulfate which is predominantly used as a main ingredient in nutraceutical and veterinary formulations.
Our Chondroitin sulfate is compliant with the most restrictive and up-to-date monographs (EP, USP, JP, KP, RP) and is GMP certified.
Product information
SOURCE: Bovine or porcine cartilage.
PURITY: 90-100%
USES:
Pharmaceuticals
Injectable products
Nutraceuticals
QUALITIES: European, United States, Japanese, Korean and Russian Pharmacopoeias.
DMFs/CERTIFICATIONS:
DMF for all qualities on demand
Europe: CEP (double) TSE
Japan: Accreditation certified by foreign drug manufacturer
Korea: KFDA registration
GMP certificate
INDICATION: For the symptomatic treatment of osteoarthritis.